Journal article
Single-cell transcriptomic landscape deciphers intratumoral heterogeneity and subtypes of acral and mucosal melanoma
- Abstract:
-
Purpose:
To identify the specific intratumoral and microenvironmental heterogeneity of acral (AM) and mucosal melanoma (MM), we aimed to delineate their distinct cellular compositions, evolutionary trajectories, and subtype-specific therapeutic strategies.
Experimental Design:
Single-cell transcriptomic and genomic landscapes were analyzed across 42 melanoma samples (28 AM, 11 MM, and 3 non-acral cutaneous melanoma [CM]), supplemented by in vitro and in vivo validation. Tumor and stromal cells were profiled using scRNA-seq, whole-exome sequencing, and functional assays, including transwell migration, co-culture systems, and xenograft models.
Results:
Tumor cells exhibited divergent evolutionary routes, with MM dominated by MGP⁺/PCOLCE⁺ subpopulations showing high epithelial-to-mesenchymal transition (EMT) potential. MM displayed elevated neutrophil infiltration and CXCL3⁺ tumor-associated macrophages, while AM was enriched with PI16⁺ cancer-associated fibroblasts (CAFs) promoting tumor proliferation. Molecular classification revealed MM subtypes: an antigen-presenting subtype linked to favorable outcomes and a proliferative subtype associated with recurrence. TIGIT⁺ Treg cells were enriched in AM, suggesting targeted inhibition potential. Genomic analysis connected BRAF/NRAS mutations to ALDOA⁺ stem-like tumor cells and identified PTGDS as a therapeutic target in triple-WT melanomas.
Conclusions:
Our study provides a comprehensive comparison of AM and MM, uncovering subtype-specific stromal-immune interactions and molecular programs. The findings highlight actionable targets (e.g., TIGIT in AM, CXCL3⁺ macrophages in MM) and propose a framework for precision therapies, biomarker-driven trials, and risk stratification to improve outcomes in these aggressive melanomas.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 16.7MB, Terms of use)
-
(Supplementary materials, zip, 15.2MB, Terms of use)
-
- Publisher copy:
- 10.1158/1078-0432.ccr-24-3164
Authors
+ National Natural Science Foundation of China
More from this funder
- Funder identifier:
- https://ror.org/01h0zpd94
- Grant:
- U21A20379
+ National Key Research and Development Program of China
More from this funder
- Grant:
- 2021YFA1101000
- 2021YFA1101004
- Publisher:
- American Association for Cancer Research (AACR)
- Journal:
- Clinical Cancer Research More from this journal
- Volume:
- 31
- Issue:
- 12
- Pages:
- 2495–2514
- Place of publication:
- United States
- Publication date:
- 2025-04-07
- Acceptance date:
- 2025-04-03
- DOI:
- EISSN:
-
1557-3265
- ISSN:
-
1078-0432
- Pmid:
-
40192737
- Language:
-
English
- Pubs id:
-
2117089
- Local pid:
-
pubs:2117089
- Deposit date:
-
2025-05-01
- ARK identifier:
Terms of use
- Copyright holder:
- Li et al.
- Copyright date:
- 2025
- Rights statement:
- ©2025 The Authors; Published by the American Association for Cancer Research This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.
If you are the owner of this record, you can report an update to it here: Report update to this record